homefeedbacksupportlog on 4-Jul-2008 
  About F1000

 What is F1000 Biology?
 Key features
 How it's organized
 FAQs
 Faculties and sections
 Scope of sections
 List of Faculty Members
 The evaluation system
 Citing F1000
 Take a tour of the site
 Accessing fulltexts
 PubMed linkout
 How to subscribe
 Academic subscriptions
 Corporate subscriptions
 Try F1000 for free
 Who we are
 Media information
 Librarian resources
 Press releases
 In the press
 Developing countries
 F1000 Medicine
 Terms and conditions
 Privacy policy
 Contact us


Robert Kerbel
University of Toronto, Canada

Faculty Member: PHARMACOLOGY & DRUG DISCOVERY > Cancer therapeutics [ since 30 May 2006 ]
[ Evaluations ]
to email [Help]
Evaluations

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
Fischer C, Jonckx B, …, Collen D, Carmeliet P
Cell 2007 Nov 2 131(3):463-75 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Andrius Kazlauskas / Robert Kerbel
Evaluated 21 Dec 2007

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.
Shojaei F, Wu X, …, Gerber HP, Ferrara N
Nat Biotechnol 2007 Aug 25(8):911-20 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Kranz / Robert Kerbel
Evaluated 19 Sep 2007

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR, Davis R, …, Hu-Lowe DD, McDonald DM
J Clin Invest 2006 Oct 116(10):2610-21 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Robert Kerbel
Evaluated 5 Jan 2007

^Top  Back to Faculty Members


© 1999-2008 Biology Reports Ltd unless otherwise stated < info@f1000.com >   Terms and conditions   Legal info